Article
Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.
Scientific reports - 31 Mar 2017
Takeda Haruhiko, Ueda Yoshihide, Inuzuka Tadashi, Yamashita Yukitaka, Osaki Yukio, Nasu Akihiro, Umeda Makoto, Takemura Ryo, Seno Hiroshi, Sekine Akihiro, Marusawa Hiroyuki
Abstract excerpt
Resistance-associated variant (RAV) is one of the most significant clinical challenges in treating HCV-infected patients with direct-acting antivirals (DAAs). We investigated the viral dynamics in patients receiving DAAs using third-generation sequencing technology. Among 283 patients with genotype-1b HCV receiving daclatasvir + asunaprevir (DCV/ASV), 32 (11.3%) failed to achieve sustained virological response...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.